Tag: SIR-spheres

Establishing the evidence base for SIRT in Interventional Oncology

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

SIRT fails to extend survival in the SORAMIC study palliative cohort

  The SORAMIC study, presented at The International Liver Congress, shows that the addition of selective internal radiation therapy (SIRT) to sorafenib in patients with...

Varian signs agreement to acquire Sirtex

Varian Medical has announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical for A$28 per share in cash....

Right-side survival data from SIRFLOX/FOXFIRE global studies presented at WCGIC

Sirtex has announced the presentation of the SIRFLOX/FOXFIRE Global right-side survival data in metastatic colorectal cancer at the 19th European Society for Medical Oncology...

SIRveNIB abstract published by ASCO, to be presented on 4 June

SIRveNIB is an investigator-led Asia Pacific Primary Liver Cancer Study to be presented on 4 June 2017 at the American Society of Clinical Oncology...

REsect study shows SIRT makes metastatic colorectal cancer patients more likely...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

SARAH study results to be presented as oral abstract at April...

Sirtex has announced that the SARAH (Sorafenib vs. radioembolisation in advanced hepatocellular carcinoma) randomised controlled study results will be presented at the upcoming European...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...